Trials / Recruiting
RecruitingNCT06662760
Clinical Trial of TQB3002 in Patients With Advanced Cancers
A Phase I Clinical Study of TQB3002 in Patients With Advanced Cancers
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase I study to evaluate the safety, tolerability, and efficacy of TQB3002 in subjects with advanced cancers
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQB3002 Tablets | TQB3002 is a fourth-generation small molecule Epidermal growth factor receptor (EGFR) inhibitor, which inhibits relevant tyrosine kinase activity and intracellular phosphorylation process by competitively binding to Adenosine triphosphate (ATP) site of intracellular tyrosine kinase binding domain, thereby inhibiting EGFR downstream signaling, ultimately achieving the purpose of inhibiting tumor growth. |
Timeline
- Start date
- 2024-12-09
- Primary completion
- 2025-11-01
- Completion
- 2026-10-01
- First posted
- 2024-10-29
- Last updated
- 2025-11-25
Locations
11 sites across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06662760. Inclusion in this directory is not an endorsement.